Entera Bio Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Entera Bio Ltd., a foreign private issuer, covers the month of December 2019. The report, dated December 18, 2019, consists solely of a press release issued by the company on that date, which is attached as Exhibit 99.1 and incorporated by reference.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a conduit for a press release and does not contain a financial statement or quantitative performance data within the provided text.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. No comparative financial data or operational metrics are included in the excerpt.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. While the filing incorporates a press release, the specific content of that release is not detailed in the provided text.
Key Facts for Investor Verification
- The filing is a Form 6-K referencing a press release dated December 18, 2019.
- The registrant is Entera Bio Ltd., headquartered in Jerusalem, Israel.
- The document does not contain standalone financial data; investors must review the attached Exhibit 99.1 for specific details.
- The report was signed by Adam Gridley, Chief Executive Officer.